Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Background: We evaluated the effects of low doses of the tyrosine kinase Abelson (Abl) inhibitor Nilotinib, on safety and pharmacokinetics in Parkinson’s disease dementia or dementia with Lewy bodies. Objectives: The primary outcomes of this study were safety and tolerability; pharmacokinetics and target engagement were secondary, while clinical outcomes were exploratory. Methods: Twelve subjects were randomized into 150 mg ( n = 5) or 300 mg ( n = 7) groups and received Nilotinib orally every day for 24 weeks. Results: This study shows that 150 mg and 300 mg doses of Nilotinib appear to be safe and tolerated in subjects with advanced Parkinson’s disease. Nilotinib is detectable in the cerebrospinal fluid (CSF) and seems to engage the target Abl. Motor and cognitive outcomes suggest a possible beneficial effect on clinical outcomes. The CSF levels of homovanillic acid are significantly increased between baseline and 24 weeks of treatment. Exploratory CSF biomarkers were measured. Conclusions: This small proof-of-concept study lacks a placebo group and participants were not homogenous, resulting in baseline differences between and within groups. This limits the interpretations of the biomarker and clinical data, and any conclusions should be drawn cautiously. Nonetheless, the collective observations suggest that it is warranted to evaluate the safety and efficacy of Nilotinib in larger randomized, double-blind, placebo-controlled trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Nilotinib, proven to improve mitochondrial function,517 and clinical trials have been initiated to explore its application in PD.518,519”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [519]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ubiquitination Increases Parkin Activity to Promote Autophagic α-Synuclein Clearance
Lonskaya, I., Desforges, N. M., Hebron, M. L., & Moussa, C. E.-H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083914 · Cited by 86
Self-citationRetractedRepertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Cui, C., Cui, J., Jin, F., Cui, Y., Li, R., Jiang, X., Tian, Y., Wang, K., Jiang, P., & Gao, J. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479571 · Cited by 5,203
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
mTOR and cancer: insights into a complex relationship
Sabatini, D. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1974 · Cited by 1,322
Boland, B., Kumar, A., Lee, S., Platt, F. M., Wegiel, J., Yu, W. H., & Nixon, R. A. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.0800-08.2008 · Cited by 1,119
Aggregate-prone proteins with polyglutamine and polyalanine expansions are degraded by autophagy
Ravikumar, B. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.9.1107 · Cited by 1,111
DJ‐1 has a role in antioxidative stress to prevent cell death
Taira, T., Saito, Y., Niki, T., Iguchi‐Ariga, S. M. M., Takahashi, K., & Ariga, H. (2004) · EMBO reports · doi:10.1038/sj.embor.7400074 · Cited by 853
Research works printed but not linked: 2
- 10.1007/s00109-013-1112-3 · DOI · Paper page
- Kang JH, 2013, JAMA Neurol, 70, 1277
Cited by
Items 201–284 of 284
Anticancer drugs for Parkinson's disease: Is it a ray of hope or only hype?
Goyal, V., & Dash, D. (2018) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_177_18 · Cited by 5
Lin, Y. M., Banoth, D., Wali, M. H., Bekova, K., Abdulla, N., Gurugubelli, S., & Khan, S. (2024) · Cureus · doi:10.7759/cureus.64766 · Cited by 5
Schwarzschild, M. A. (2016) · Journal of Parkinson s Disease · doi:10.3233/jpd-160975 · Cited by 4
Neuroprotection in Parkinson Disease
Jain, K. K. (2019) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4939-9465-6_7 · Cited by 4
Nanobiotechnology in Parkinson’s Disease
Torres-Ortega, P. V., Martínez-Valbuena, I., Martí‐Andrés, G., Hanafy, A. S., Luquin, M. R., Garbayo, E., & Blanco‐Prieto, M. J. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_7 · Cited by 4
Mansour, H. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102195 · Cited by 3
Zenuni, H., Candelise, N., Grillo, P., Simonetta, C., Bovenzi, R., Ferri, A., Valle, C., Mercuri, N. B., & Schirinzi, T. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2106165 · Cited by 3
Frontotemporal lobar degeneration
Kim, B., Viera-Ortiz, A., Phan, J. M., Irwin, D. J., & Lee, E. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00041-1 · Cited by 3
Tau in Tauopathies That Leads to Cognitive Disorders and in Cancer
Huda, M. N., & Pan, C. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.74025 · Cited by 3
Panza, F., Lozupone, M., Watling, M., & Imbimbo, B. P. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1828350 · Cited by 3
Non-conducting functions of potassium channels in cancer and neurological disease
Sesti, F., Bortolami, A., & Forzisi, E. (2023) · Current topics in membranes · doi:10.1016/bs.ctm.2023.09.007 · Cited by 3
A case report of multiple system atrophy treated with an Abelson tyrosine kinase inhibitor
Ngoc, T. V. N., Huu, C. N., & Truong, D. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.09.013 · Cited by 3
Advancements in Brain Diseases: Exploring the Complexities and Pursuing Therapeutic BreakthroughsPreprint
Mutery, A. A., Hussain, I., & Mumtaz, K. (2023) · Preprints.org · doi:10.20944/preprints202309.0701.v1 · Cited by 3
Kim, J.-E., Wang, S. H., & Kang, T. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110586 · Cited by 2
The challenges of experimental pharmacology in identifying novel treatments for Parkinson's disease
Teil, M., & Huot, P. (2026) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2025.103164 · Cited by 2
Drug repurposing for disease-modifying effects in multiple system atrophy
Jeong, S. H., Shin, J. Y., & Lee, P. H. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00551-7 · Cited by 2
Current Therapeutic Options and Repurposed Drugs for Neurodegeneration
Dhaneshwar, S. S., Bhat, M. A., Singh, A., & Roy, S. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815238754124010012 · Cited by 2
Neuroprotective Action of Polyphenols and Phenolic Compounds: An Overview
Khairnar, S. J., & Jadhav, G. B. (2023) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3132 · Cited by 2
Neuroprotective Activity of a Non-Covalent Imatinib+TP10 Conjugate in HT-22 Neuronal Cells In Vitro
Rusiecka, I., Gągało, I., & Kocić, I. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060778 · Cited by 2
Chan, J., Shah, P., & Moguel‐Cobos, G. (2019) · Case Reports in Neurological Medicine · doi:10.1155/2019/3679319 · Cited by 2
Parkinson's disease and social media
Al-Busaidi, I. S., & Alamri, Y. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815946-0.00008-9 · Cited by 2
Therapeutic trials in dementia with Lewy bodies: a systematic review of the literature
Sacrez, M., Lamothe, M., Rauch, L., Botzung, A., & Blanc, F. (2021) · Gériatrie et Psychologie Neuropsychiatrie du Viellissement · doi:10.1684/pnv.2021.0947 · Cited by 2
An Antifungal for Antidiuresis?
Verbalis, J. G. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2019030285 · Cited by 2
Autophagy Mechanisms for Brain Recovery. Keep It Clean, Keep It Alive
Nobili, A., Barbera, L. L., Mastrantonio, R., Palazzo, C., Molinari, M., D’Amelio, M., & Viscomi, M. T. (2023) · Contemporary clinical neuroscience · doi:10.1007/978-3-031-24930-3_2 · Cited by 1
Advances in Disease Modifying Therapies for Parkinson's Disease
Hassanzadeh, K., & Mouradian, M. M. (2025) · Wiley eBooks · doi:10.1002/9783527844678.ch2 · Cited by 1
Ezeldine-Elmahalawy, N., Abdelkader, N. F., Zaki, H. F., El-Brairy, A. I., & Gad, S. S. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01933-5 · Cited by 1
Corticobasal Degeneration: A Review
Lopez, A. M., Johnson, S., Wax, N., Cutchin, C., May, D., Curtain, T., Bynum, Z., Galliher, M., Jones Diamond, A., Sudhakar, S., et al. (2025) · Journal of Neuroscience and Neurological Disorders · doi:10.29328/journal.jnnd.1001113 · Cited by 1
A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
Eijsvogel, P. P. N. M., Smits, L. M. G., Kremer, P. H. C., & Groeneveld, G. J. (2026) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70315 · Cited by 1
Wang, W., & Meng, X. (2026) · Frontiers in Neuroscience · doi:10.3389/fnins.2026.1819002 · Cited by 1
Ariyath, A., Arigo, F. D., Fyfe, A., Fernando, W. M. A. D. B., Martins, R. N., & Bharadwaj, P. (2026) · Journal of Neurochemistry · doi:10.1111/jnc.70473 · Cited by 1
Wrasidlo, W., & Masliah, E. (2026) · Cells · doi:10.3390/cells15131177 · Cited by 1
Wittström, F., Chen, E. Y., Blotenberg, I., & Dahlén, T. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71916 · Cited by 1
Neue Kriterien für die Diagnose der Demenz mit Lewy-Körpern
Wagner, A. S., Tönnies, E., Sennock, S., Leikeim, L., Gronewold, A., Klag, J., & Dodel, R. C. (2017) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-017-2088-2 · Cited by 1
Disease modification trials in parkinsons disease: A Review
Hashmi, R. N., & Kiram, U. (2020) · Pakistan Journal of Neurological Sciences · Cited by 1
Lee, M., Mahy, W., & Rackham, M. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00113b
Efficacy of nilotinib in monozygotic twins with spinocerebellar ataxia type 6
Choi, S., Kim, H., Choi, K., & Kim, J. (2021) · Journal of Neurology · doi:10.1007/s00415-021-10895-x · Cited by 1
Paik, J. (2022) · Drugs & Therapy Perspectives · doi:10.1007/s40267-022-00950-6 · Cited by 1
Clinical aspects and in vitro modelling of GBA1 variant-associated Parkinson's disease
Stoker, T. B. (2019) · Apollo (University of Cambridge) · doi:10.17863/cam.49065 · Cited by 1
Enfermedad de Parkinson. Últimos avances en el tratamiento
Gallego, S. R., & Juárez, G. T. (2017) · Docta Complutense (Universidad Complutense de Madrid) · Cited by 1
Could cancer drugs be repurposed for use in Parkinson’s and Alzheimer’s?
Moussa, C. (2016) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2016.1248411
Self-citationNeurodegenerative Diseases: Parkinson’s and Alzheimer’s Diseases
Ellenstein, A., Prather, C. P., & Коган, М. И. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190466268.003.0020
Repurposing Clinic-Tested Drugs to Treat Rare Neurogenetic Diseases by Transcriptional Modulation
Hadwen, J. (2018) · uO Research (University of Ottawa) · doi:10.20381/ruor-21849
Macroautophagy, alpha-synuclein and dopamine neurotransmission: implications for Parkinson’s disease
Hunn, B. H. M. (2017) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-gwnpnvjed
Wallings, R. L. (2018) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-dxp7zmjay
Pick the Company 企業紹介(第76回 2)株式会社TV・ポータル
平田, 和., & 武居, 邦. (2010) · 衛星&ケーブルテレビ
Anttila, S. (2019) · UTUPub (University of Turku)
Phase 2 Nilotinib Trials for Parkinson's Yield Conflicting Efficacy Results
Samson, K. (2020) · Neurology Today · doi:10.1097/01.nt.0000662128.13325.97
Generation and Applications of Knowledge Graphs in Systems and Networks Biology
Hoyt, C. T. (2019) · bonndoc (University of Bonn)
Parkinson's disease: Genetic-driven therapeutic approaches
Sardi, S. P., & Baptista, M. A. S. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816475-4.00008-2
Jankovic, J. J., & Tarakad, A. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733126426.793546305
(2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-209005
Development of autophagy enhancers for Parkinson’s disease therapy
Sasazawa, Y., Hattori, N., & Saiki, S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89906-2.00003-4
Pharmacotherapy of Alzheimer's disease: A thorny road to success
Ibrahim, N. H., Kumar, J., & Mohamed, W. M. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00027-0
Nobel prize-winning autophagy research laid groundwork for potential Parkinson’s treatment
Moussa, C. (2016) · The Conversation · doi:10.64628/aai.m5jycnucj
Self-citationSierra-Contreras, K. L., Jiménez-Acosta, V., Noguera-Rosero, S., Rodríguez, D. C., & Orjuela-Cañón, Á. D. (2025) · IEEE Colombian BioCAS Workshop · doi:10.1109/colbiocas66416.2025.11276152
Investigating oligodendrocyte dysfunction in Huntington's Disease using oligocortical organoids
Witt, S. I. (2025) · cIRcle (University of British Columbia) · doi:10.14288/1.0444027
Kim, J., Lee, H.-J., Park, J.-H., Cha, B.-Y., & Hoe, H.-S. (2022) · Figshare · doi:10.6084/m9.figshare.20329567
Stevenson, M. E., Varghese, R., Hebron, M. L., Liu, X., Ratliff, N., Smith, A., Turner, R. S., & Moussa, C. (2024) · Figshare · doi:10.6084/m9.figshare.26589822
Self-citationRodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Ruiz, C. A., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J., Pilotto, A., Rongve, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19689331
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Ruiz, C. A., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J., Pilotto, A., Rongve, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19689334
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Ruiz, C. A., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J., Pilotto, A., Rongve, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19689340
Rodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Ruiz, C. A., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J., Pilotto, A., Rongve, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19689343
Stevenson, M. E., Varghese, R., Hebron, M. L., Liu, X., Ratliff, N., Smith, A., Turner, R. S., & Moussa, C. (2024) · Figshare · doi:10.6084/m9.figshare.26589819
Self-citationRodriguez‐Porcel, F. E., Wyman‐Chick, K. A., Ruiz, C. A., Toledo, J. B., Ferreira, D., Urwyler, P., Weil, R. S., Kane, J., Pilotto, A., Rongve, A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19689337
Stevenson, M. E. (2024) · DigitalGeorgetown (Georgetown University Library)
Modeling and Simulation of Drug Distribution in the Central Nervous System
Heitman, A. (2022) · DigitalGeorgetown (Georgetown University Library)
Proteina a-sinucleina como alvo terapeutico no tratamento da doença de Parkinson
Caldeira, M. A. B. (2020) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Drug Repositioning and Repurposing for Neurodegenerative Diseases
Pawar, K. V., Srinu, S., & Sharma, A. (2026) · Springer eBooks · doi:10.1007/978-981-95-5088-3_13
Modélisation et recherche de stratégies expérimentales dans l’atrophie multisystématisée
Guerin, P. A. (2018) · theses.fr (ABES) · doi:10.70675/b4a315bfz31baz46d1z9e9fz88481e022180
Arotçarena, M.-L. (2019) · theses.fr (ABES) · doi:10.70675/fc7ae442z6823z43c3z8ebazd4960299833b
Etude des mécanismes et cibles thérapeutiques des synucléinopathies
Teil, M. (2021) · theses.fr (ABES) · doi:10.70675/3fab2d7fz6930z4bdcz8e62z51f35aa732ec
Novel treatments for Parkinson’s disease
Yin, Y., Gao, J., Zhang, K., Meng, F. D., & Feng, T. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004163
Yang, F. Y. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1805370
Gaur, P. K., Bisht, P. R., & Gupta, S. L. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2723464
Erdem, M., Erdem, Ş., & Karahan, S. C. (2026) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2026.579084
Bedage, P. L., Dhanush, Y., Chettri, P., Shivakumar, Ahmed, S. S., & Raghunathanaidu, B. D. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06207-x
BindingDB (2020) · UC San Diego · doi:10.7270/q24170kg
Supporting information 1 of Nilotinib in Parkinson's disease: A systematic review and meta-analysis
Xie, X., Yuan, P., Kou, L., Chen, X., Li, J., & Li, Y. (2022) · doi:10.3389/fnagi.2022.996217.s001
Marín, T., Dulcey, A. E., Campos, F., de la Fuente, C., Acuña, M., Castro, J., Pinto, C., Yañez, M. J., Cortez, C., McGrath, D. W., et al. (2022) · doi:10.3389/fcell.2022.844297.s001
Metadata
- Authors
- Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., Lawler, A., Rogers, S. L., Falconer, R. A., Ahn, J., Li, Z., & Moussa, C.
- Affiliations
- Department of Neurology, National Parkinson’s Foundation Center for Excellence, Translational Neurotherapeutics Program. Movement Disorders Program. MedStar Georgetown Hospital Washington, DC, USA
- Georgetown University Medical Center (US)
- MedStar Georgetown University Hospital (US)
- Corresponding author
- Moussa, Charbel
- Venue
- Journal of Parkinson’s Disease
- Publisher
- SAGE Publications
- Published
- 2016-06-03
- Volume
- 6
- Issue
- 3
- Pages
- 503-517
- ISSN
- 1877-7171 (ISSN-L)
- 1877-718X
- PMC
- PMC5008228
- OpenAlex
- W2462137239
- Cited by
- 265
- References
- 49
- Citations by year
- 2026: 14 · 2025: 12 · 2024: 20 · 2023: 23 · 2022: 37 · 2021: 34 · 2020: 32 · 2019: 38 · 2018: 30 · 2017: 17 · 2016: 7
- FWCI
- 23.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Parkinson s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- U.S. Department of Health and Human Services (UL1RR031975)
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001409, UL1TR000101)
- National Center for Research Resources (UL1RR031975)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- nilotinib, Parkinson's disease, dementia with Lewy bodies, ABL tyrosine kinase inhibitors, cerebrospinal fluid pharmacokinetics, target engagement, homovanillic acid, cerebrospinal fluid biomarkers, drug safety and tolerability
- MeSH terms
- Dementia, Follow-Up Studies, Humans, Parkinson Disease, Pyrimidines, Outcome Assessment, Health Care, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.